UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The patent provides protection until 2037 in this market.
"We are delighted to see that our delivery technology has received IP validation in yet another important market,” said Nina Herne, CEO of LIDDS.
Recently, LIDDS has received patent approval in China (patent no. 2017800630120). The invention covering process and products based on the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. During 2021 the same patent family has also received approvals in Russia, Australia, India, South Africa and Singapore. The patent and a related divisional patent are already approved in the US as previously communicated.
For more information, please contact:
Nina Herne, CEO, +46 (0)70 714 7457, e-mail: nina.herne@liddspharma.com
The information was submitted for publication, through the agency of the aforementioned contact person, on Dedember 17 at 09.30 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company focusing on a unique proprietary drug delivery technology: NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North Growth Market ( ticker LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com.
